Date: 2013-11-18
Type of information: Development agreement
Compound: companion diagnostics
Company: Qiagen (The Netherlands) Eli Lilly (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
commercialisation
Action mechanism:
Disease:
Details: * On November 18, 2013, Qiagen has announced an agreement with Eli Lilly to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by Qiagen and Lilly to create companion diagnostics. The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed in February. In September 2011, Qiagen and Lilly partnered to develop a companion diagnostic that evaluates the Janus kinase 2 (JAK2) gene, which plays a role in some blood cancers. The test is paired with a Lilly compound to guide use of the proposed drug, currently in clinical trials.
The Lilly co-development program and others are designing companion diagnostics that offer laboratories an efficient workflow on QIAGEN’s Rotor-Gene Q MDx instrument using real-time PCR technology. The Rotor-Gene Q MDx is part of the QIAsymphony family of automated platforms.
* On February 13, 2013, Qiagen has entered into a master collaboration agreement with Eli Lilly for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on Qiagen and Lilly's past work together. The agreement provides a framework for Lilly and Qiagen to collaborate on future projects - across all of Lilly's therapeutic areas - aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.
Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments. Qiagen's strategy is to develop FDA-approved diagnostics in the United States for use on this platform.
Financial terms: Financial terms of the agreement are not being disclosed.
Latest news:
